Stealth BioTherapeutics to Present at the 2015 Leerink Global Healthcare Conference

February 04, 2015

Presentation will be on Wednesday, February 11, 2015 at 2:15pm EST

Boston, MA – February 4, 2015 – Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today announced that Chief Executive Officer Travis Wilson will present a corporate overview and update at the 2015 Leerink Global Healthcare Conference.

The presentation will take place on Wednesday, February 11, 2015 at 2:15 p.m. EST at the Waldorf Astoria in New York, NY.

Stealth BioTherapeutics: Leading Mitochondrial Medicine

Stealth BioTherapeutics is a privately-held biopharmaceutical company committed to bringing mitochondria therapies to patients to treat both common and rare diseases. As a key common element in a variety of serious, debilitating diseases, mitochondria – the cell’s energy source – offer a promising, and yet untapped, target to modify diseases with significant unmet treatment needs. Stealth is expanding its clinical development program to additional therapeutic areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases. By defining the broad potential of its mitochondrial platform and therapies, Stealth is leading mitochondrial medicine.

More information regarding Stealth and its pipeline is available at


Media Relations:
dna communications
Taylor Ramsey
Phone: (617) 520-7018

Investor Relations:
Stern IR
Beth DelGiacco
Phone: (212) 362-1200

Media Relations

dna Communications
Lindsey Colegrove, 212-537-8771

Investor Inquiries
Stern IR
Lauren Stival, 212-362-1200